France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in ...

Sanofi SA (NASDAQ:SNY) on Monday agreed to acquire Blueprint Medicines Corporation (NASDAQ:BPMC). The acquisition includes a ...

Sanofi has agreed to acquire Blueprint Medicines for $9.1 billion, expanding its footprint in rare immunological diseases. The purchase includes a 27% premium per share and could total nearly $9.5 ...

Sanofi has signed an agreement to acquire US-based Blueprint Medicines to bolster its immunology pipeline with rare disease treatments.

French drugmaker Sanofi said Monday it has agreed to acquire Blueprint Medicines for up to $9.5 billion, sending shares of the Cambridge, Mass.-based biopharma firm soaring in intraday trading.

From new industry M&As to insights on how to recruit Gen Z talent, there’s plenty to discover in our latest pharma news round ...

Sanofi acquires Blueprint Medicines for $9.1 billion, gaining Ayvakit, a rare disease treatment approved in the US and EU for multiple conditions.

Sanofi and Blueprint Medicines, a U.S.-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, and other KIT-driven diseases, ...

The Blueprint deal comes after Sanofi made an unsuccessful play in 2022 for another rare disease specialist, Horizon Therapeutics. In that case, Amgen took the prize with its $27.8 billion offer.

Sanofi acquires Blueprint Medicines Corporation for $9.1bn, gaining revenue-driving Aykavit and pipeline drug BLU-808 potential. Click for more on SNY and BPMC.